tanshinone, tanshinone I, tanshinone II A, tanshinone II B, tanshinone IIA, tanshinone IIB, TTE-50
Name | Tanshinone I | ||
PubChem CID | 114917 | ||
Molecular Weight | 276.3g/mol | ||
Synonyms |
tanshinone, tanshinone I, tanshinone II A, tanshinone II B, tanshinone IIA, tanshinone IIB, TTE-50 |
||
Formula | C₁₈H₁₂O₃ | ||
SMILES | CC1=C2C=CC3=C(C2=CC=C1)C(=O)C(=O)C4=C3OC=C4C | ||
InChI | 1S/C18H12O3/c1-9-4-3-5-12-11(9)6-7-13-15(12)17(20)16(19)14-10(2)8-21-18(13)14/h3-8H,1-2H3 | ||
InChIKey | AIGAZQPHXLWMOJ-UHFFFAOYSA-N | ||
CAS Number | 568-73-0 | ||
ChEMBL ID | CHEMBL363535 | ||
ChEBI ID | CHEBI:149906 | ||
Drug Bank ID | DB16886 | ||
Structure |
Download
2D
MOL
3D
MOL
|
Chineses Pinyin | DanShen | ||
Use Part | Root | ||
Habitat | GanSu, SiChuan, GuiZhou | ||
Flavor | Bitter | ||
Meridian Tropism | Heart; Liver | ||
Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Lamiales
-->Family: Lamiaceae
-->Genus: Salvia
-->Species: Salvia miltiorrhiza
|
Pair Name | Tanshinone I, Paclitaxel | |||
Partner Name | Paclitaxel | |||
Disease Info | [ICD-11: 2C73] | Ovarian cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BCL2 | hsa596 | |
Up-regulation | Expression | CDKN1A | hsa1026 | |
Up-regulation | Expression | CDKN2A | hsa1029 | |
In Vitro Model | A2780 | Ovarian endometrioid adenocarcinoma | Homo sapiens (Human) | CVCL_0134 |
ID8 | Epithelial Ovarian Cancer | Mus musculus (Mouse) | CVCL_IU14 | |
In Vivo Model | The A2780 cells were injected bilaterally and subcutaneously into the flanks of the nude mice (100 µL, 2×10⁷ cells). | |||
Result | Natural compound Tan-I enhances the efficacy of ovarian cancer to Paclitaxel chemotherapy. The results will help to supply the potential clinical use of ovarian carcinoma cells. |
Pair Name | Tanshinone I, Lenalidomide | |||
Partner Name | Lenalidomide | |||
Disease Info | [ICD-11: 2A83] | Multiple myeloma | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | ACD | hsa65057 |
Down-regulation | Expression | TERF2IP | hsa54386 | |
Down-regulation | Expression | TNKS | hsa8658 | |
In Vitro Model | RPMI-8226 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_0014 |
U266B1 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_0566 | |
Result | Combination of TanI with standard chemotherapeutic drug Len, potentiates cell death in myeloma cells |
Pair Name | Tanshinone I, Epirubicin | |||
Partner Name | Epirubicin | |||
Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
Gene Regulation | Down-regulation | Expression | AKT1 | hsa207 |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Up-regulation | Cleavage | CASP9 | hsa842 | |
Down-regulation | Expression | HIF1A | hsa3091 | |
Down-regulation | Expression | PIK3CA | hsa5290 | |
In Vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 |
Huh-7 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0336 | |
In Vivo Model | 2×10⁶ HepG2 vector cells (100 μL) were injected subcutaneously into the left and right flanks of nude mice in the vector group. And 2×10*6 HepG2 HIF-1α cells (100 μL) were injected subcutaneously into the left and right flanks of nude mice in the HIF-1α group. | |||
Result | Our results suggested that Tan I could effectively improve the anti-tumor effect of EADM, and synergize EADM to reverse HIF-1α mediated resistance via targeting PI3K/AKT/HIF-1α signaling pathway. |
No. | Title | Href |
---|---|---|
1 | Natural compound Tan-I enhances the efficacy of Paclitaxel chemotherapy in ovarian cancer. Ann Transl Med. 2020 Jun;8(12):752. doi: 10.21037/atm-20-4072. | Click |
2 | Novel combination of tanshinone I and lenalidomide induces chemo-sensitivity in myeloma cells by modulating telomerase activity and expression of shelterin complex and its associated molecules. Mol Biol Rep. 2018 Dec;45(6):2429-2439. doi: 10.1007/s11033-018-4409-z. | Click |
3 | Combined Treatment of Tanshinone I and Epirubicin Revealed Enhanced Inhibition of Hepatocellular Carcinoma by Targeting PI3K/AKT/HIF-1α. Drug Des Devel Ther. 2022 Sep 19;16:3197-3213. doi: 10.2147/DDDT.S360691. | Click |